Abstract: Methods and means are described to modify fiber characteristics in a fiber producing plant, such as cotton, based on the use of a novel type of sucrose synthase protein or related nucleic acids.

Abstract: A KVM switch system having a touch screen for interacting with multiple computers is disclosed. The KVM switch processes coordinate data from the touch screen and transfers the processed data to the controlled computer either as absolute mouse coordinate data or as relative mouse coordinate data depending on the operating system (Windows, Mac OS, SUN, etc.) and mouse data interface (USB, PS/2, etc.) used by the computer. Thus, the touch screen can interact with all computers connected to the KVM switch, achieving a multi-platform and multi-interface application without requiring device drivers on the computers. The KVM switch stores necessary parameters for each computer so that when switching from one computer port to another, or when the display resolution of the computer changes, processing of the touch screen data is automatically adjusted accordingly. The touch screen also works within the OSD of the KVM switch.

Abstract: The present invention relates to a method of decreasing body weight in a patient. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to said patient. A pharmaceutical/cosmetic composition comprises the somatostatin or somatostatin agonist. Such products are used to prepare such compositions for the reduction or body weight in a human or mammalian animal.

Abstract: Methods and means are provided to modulate fiber quality in fiber-producing plants, such as cotton by modulating sucrose synthase activity and/or expression in such plants. The methods and means may also be used to obtain plants with seedless fruits or male-sterile plants.

Abstract: Methods and means are provided for modulating fiber length in fiber producing plants such as cotton by altering the fiber elongation phase. The fiber elongation phase may be increased or decreased by interfering with callose deposition in plasmodesmata at the base of the fiber cells.

Abstract: The present invention relates to a method of treating insulin resistance or Syndrome X. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to said patient. The invention also includes pharmaceutical compositions comprising a somatostatin or somatostatin agonist and the use of such products in the preparation of such compositions.

Abstract: The present invention relates to a method of treating insulin resistance or Syndrome X by administering a therapeutically effective amount of a somatostatin agonist or a pharmaceutical composition comprised of a somatostatin agonist to a patient suffering from insulin resistance or Syndrome X.

Abstract: High density plasma chemical vapor deposition and etch back processes fill high aspect ratio gaps without liner erosion or further underlying structure attack. The characteristics of the deposition process are modulated such that the deposition component of the process initially dominates the sputter component of the process. For example, reactive gasses are introduced in a gradient fashion into the HDP reactor and introduction of bias power onto the substrate is delayed and gradually increased or reactor pressure is decreased. In the case of a multi-step etch enhanced gap fill process, the invention may involve gradually modulating deposition and etch components during transitions between process steps. By carefully controlling the transitions between process steps, including the introduction of reactive species into the HDP reactor and the application of source and bias power onto the substrate, structure erosion is prevented.

Abstract: The present invention relates to a method of decreasing body weight in a patient. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist ot said patient. A pharmaceutical/cosmetic composition comprises the somatostatin or somatostatin agonist. Such products are used to prepare such compositions for the reduction or body weight in a human or mammalian animal.

Abstract: The present invention relates to a method of decreasing body weight in a patient. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to said patient. A pharmaceutical/cosmetic composition comprises the somatostatin or somatostatin agonist. Such products are used to prepare such compositions for the reduction of body weight in a human or mammalian animal.

Abstract: The present invention relates to a method of treating hyperlipidemia and to reducing triacylglycerols, glycerol and cholesterol in a patient. The method includes the step of administering a therapeutically effective amount of a type-5 selective somatostatin agonist to said patient. A pharmaceutical composition comprises said agonist and such product is used in the preparation of the composition for use in treating hyperlipidemia or reducing triacylglycerols, glycerol and cholesterol in a patient's body.

Abstract: A golf club head is provided having a substantially increased sweet spot across its club face. A preferred construction includes an annular area on a rear surface having increased thickness surrounding a central region with a balance point of the club face. The central region of the face has a generally reduced thickness that is less than the maximum of the annular area but greater than a minimum thickness at the peripheral area. The face material may be metallic, but in alternative embodiments the effective bending stiffness profiles represented by this annular area may be achieved by appropriate use of composites, for example. Methods for manufacturing a golf club head having a face with the bending stiffness profiles of the present invention include forging and machining techniques as well as laser deposition and inertia welding.

Abstract: The present invention relates to a method of treating insulin resistance or Syndrome X. The method includes the step of administering a therapeutically effective amount of a somatostatin or a somatostatin agonist to said patient. The invention also includes pharmaceutical compositions comprising a somatostatin or somatostatin agonist and the use of such products in the preparation of such compositions.

Abstract: The use of an antagonist of leptin for the manufacture of a medicament for the treamtne tof disorders resulting from deficiencies in insulin secretion, hyperglycaemia and insulin resistance.

Abstract: A golf club head is provided having a substantially increased sweet spot across its club face. A preferred construction includes an annular area on a rear surface having increased thickness surrounding a central region with a balance point of the club face. The central region of the face has a generally reduced thickness that is less than the maximum of the annular area but greater than a minimum thickness at the peripheral area. The face material may be metallic, but in alternative embodiments the effective bending stiffness profiles represented by this annular area may be achieved by appropriate use of composites, for example. Methods for manufacturing a golf club head having a face with the bending stiffness profiles of the present invention include forging and machining techniques as well as laser deposition and inertia welding.

Abstract: The use of an antagonist of leptin for the manufacture of a medicament for the treatment of disorders resulting from deficiencies in insulin secretion, hyperglycaemia and insulin resistance.

Abstract: The present invention relates to a method of treating hyperlipidemia and to reducing triacylglycerols. glycerol and cholesterol in a patient. The method includes the step of administering a therapeutically effective amount of a type-5 selective somatostatin agonist to said patient. A pharmaceutical composition comprises said agonist and such product is used in the preparation of the composition for use in treating hyperlipidemia or reducing triacylglycerols, glycerol and cholesterol in a patient's body.